Strata Critical Medical stock analysis
Want to see SRTA full AI Analyst Report?
Strata Critical Medical (SRTA) Stock Price & Analysis
SRTA Stock Chart & Stats
- Day’s Range
- $5.50 - $5.78
- 52-Week Range
- $3.95 - $6.50
- Previous Close
- $5.77
- Volume
- N/A
- Average Volume (3M)
- 1.13M
- Market Cap
- $492.15M
- Enterprise Value
- $412.80M
- Total Cash (Recent Filing)
- $41.64M
- Total Debt (Recent Filing)
- $3.62M
- Price to Earnings (P/E)
- ―
- Beta
- 1.95
- Next Earnings
- Mar 16, 2027 (Est.)
- EPS Estimate
- 0.01
- Next Dividend Ex-Date
- N/A
- Dividend Yield
- N/A
Bulls Say, Bears Say
Bulls Say
Strong Revenue And Gross Profit Growth
Robust revenue and gross profit growth indicate expanding demand and successful contribution from clinical acquisitions. The improvement also increases operating leverage and provides a stronger base for future margin expansion, supporting durable earnings growth over the next several quarters.
Very Low Financial Leverage
Minimal leverage gives Strata substantial financial flexibility while it works toward consistent profitability. A lightly indebted balance sheet reduces interest burden and refinancing exposure, allowing more internally generated cash and liquidity to support acquisitions, operations, or strategic investment.
Reaffirmed Growth And Cash-flow Targets
Reaffirmed guidance provides evidence that management continues to see a credible path toward higher revenue, EBITDA, and cash generation. Its medium-term targets and expected clinical-led growth could improve scale, mix, and free-cash-flow conversion if execution remains consistent.
Bears Say
TTM Profitability Remains Negative
Persistent operating and net losses show that the business has not yet converted revenue growth into durable GAAP earnings. Negative profitability limits internally funded expansion, weakens return generation, and leaves results more dependent on successful margin improvement and acquisition execution.
Uneven Free-cash-flow Conversion
Positive operating cash flow is encouraging, but very limited free cash flow indicates that cash conversion remains inconsistent after investment needs. This reduces the funds available for acquisitions and shareholder returns and makes the company more exposed to execution setbacks while profitability is still developing.
Logistics Revenue And Margin Pressure
Shorter donor-to-recipient distances directly reduce logistics revenue opportunities and pressure margins on owned aircraft. If this operating mix persists, the logistics segment may contribute less profit and offset some benefits from clinical growth, complicating consolidated margin expansion.
Strata Critical Medical News
SRTA FAQ
What was Strata Critical Medical’s price range in the past 12 months?
What is Strata Critical Medical’s market cap?
When is Strata Critical Medical’s upcoming earnings report date?
How were Strata Critical Medical’s earnings last quarter?
Is Strata Critical Medical overvalued?
Does Strata Critical Medical pay dividends?
What is Strata Critical Medical’s EPS estimate?
How many shares outstanding does Strata Critical Medical have?
What happened to Strata Critical Medical’s price movement after its last earnings report?
Which hedge fund is a major shareholder of Strata Critical Medical?
What is the TipRanks Smart Score and how is it calculated?
Strata Critical Medical Stock Smart Score
Company Description
Strata Critical Medical
Strata Critical Medical, Inc. is dedicated to supporting healthcare providers throughout the United States by offering swift logistical management and specialized medical assistance. A significant part of their operations involves the movement of human organs for transplant, utilizing both aerial and ground transportation methods. Founded in 2014, the organization previously operated under the name Blade Air Mobility, Inc. and is set to officially change its name to Strata Critical Medical, Inc. in August of 2025. Its primary corporate office is located in New York, New York.
- Sector
- Healthcare
- Industry
- Medical - Care Facilities
- CEO
- Melissa Tomkiel
- Employees
- 327
- Website
- www.stratacritical.com
- Address
- 666 Third Avenue, New York, NY, 10017, US
Strata Critical Medical (SRTA) Earnings & Revenues
SRTA Company Deck
SRTA Earnings Call
Earnings Call SentimentPositive
The call was strongly positive overall. Highlights included substantial revenue, EBITDA, margin and free cash flow growth; continued clinical market-share gains; early achievement of the logistics margin target; strong liquidity; acquisition capacity; and a new share repurchase authorization. The company did face seasonal transplant declines, shorter logistics distances, lower logistics revenue and year-over-year logistics gross margin, a sequential decline in clinical gross margin, elevated stock-based compensation and a GAAP loss caused by noncash items. However, management reiterated 2026 guidance and its medium-term growth targets, and the positive operating and strategic developments significantly outweighed the stated challenges.
View all SRTA earnings summariesTechnical Analysis
Overall Consensus
| Indicator | Bullish | Neutral | Bearish |
|---|---|---|---|
| Overall Consensus | 13 | 6 | 3 |
| Technical Analysis | 3 | 6 | 1 |
| Moving Averages | 10 | 0 | 2 |














